Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

1.

Second-line treatment for advanced thyroid cancer: an indication in need of randomized clinical trials.

Cohen AB, Brose MS.

J Clin Endocrinol Metab. 2014 Jun;99(6):1995-7. doi: 10.1210/jc.2014-2236. No abstract available.

PMID:
24893137
[PubMed - in process]
2.

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ; on behalf of the DECISION investigators.

Lancet. 2014 Apr 23. pii: S0140-6736(14)60421-9. doi: 10.1016/S0140-6736(14)60421-9. [Epub ahead of print]

PMID:
24768112
[PubMed - as supplied by publisher]
3.

Management of sorafenib-related adverse events: a clinician's perspective.

Brose MS, Frenette CT, Keefe SM, Stein SM.

Semin Oncol. 2014 Feb;41 Suppl 2:S1-S16. doi: 10.1053/j.seminoncol.2014.01.001. Epub 2014 Jan 9.

PMID:
24576654
[PubMed - indexed for MEDLINE]
Free Article
4.

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, Carroll WL, de Lima M, Gilbert MR, Kris MG, Marshall JL, Masters GA, O'Day SJ, Polite B, Schwartz GK, Sharma S, Thompson I, Vogelzang NJ, Roth BJ.

J Clin Oncol. 2014 Jan 10;32(2):129-60. doi: 10.1200/JCO.2013.53.7076. Epub 2013 Dec 10.

PMID:
24327669
[PubMed - indexed for MEDLINE]
5.

Cabozantinib in progressive medullary thyroid cancer.

Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI.

J Clin Oncol. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3.

PMID:
24002501
[PubMed - indexed for MEDLINE]
6.

Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, Bible KC, Shah MH, Gramza AW, Klopper JP, Marlow LA, Heckman MG, Von Roemeling R.

J Clin Endocrinol Metab. 2013 Jun;98(6):2392-400. doi: 10.1210/jc.2013-1106. Epub 2013 Apr 15.

PMID:
23589525
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Physician and stakeholder perceptions of conflict of interest policies in oncology.

Lockhart AC, Brose MS, Kim ES, Johnson DH, Peppercorn JM, Michels DL, Storm CD, Schuchter LM, Rathmell WK.

J Clin Oncol. 2013 May 1;31(13):1677-82. doi: 10.1200/JCO.2012.47.5475. Epub 2013 Mar 25.

PMID:
23530092
[PubMed - indexed for MEDLINE]
8.

Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology.

Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, Brose MS, Ellis LM, Erba H, George DJ, Gilbert MR, Jacobson JO, Larsen EC, Lichtman SM, Partridge AH, Patel JD, Quinn DI, Robison LL, von Roenn JH, Samlowski W, Schwartz GK, Vogelzang NJ.

J Clin Oncol. 2013 Jan 1;31(1):131-61. doi: 10.1200/JCO.2012.47.1938. Epub 2012 Dec 3. No abstract available. Erratum in: J Clin Oncol. 2013 Jun 1;31(16):2063.

PMID:
23213095
[PubMed - indexed for MEDLINE]
9.

Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma.

Brose MS, Smit J, Capdevila J, Elisei R, Nutting C, Pitoia F, Robinson B, Schlumberger M, Shong YK, Takami H.

Expert Rev Anticancer Ther. 2012 Sep;12(9):1137-47. doi: 10.1586/era.12.96.

PMID:
23098114
[PubMed - indexed for MEDLINE]
10.

RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells.

Dong X, Tang W, Stopenski S, Brose MS, Korch C, Meinkoth JL.

Endocr Relat Cancer. 2012 Jul 22;19(4):575-88. doi: 10.1530/ERC-12-0086. Print 2012 Aug.

PMID:
22696507
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, McGettigan S, Giles LR, Schuchter LM, Seykora JT, Rosenbach M.

J Am Acad Dermatol. 2012 Dec;67(6):1265-72. doi: 10.1016/j.jaad.2012.04.008. Epub 2012 May 18.

PMID:
22609219
[PubMed - indexed for MEDLINE]
12.

In search of a real "targeted" therapy for thyroid cancer.

Brose MS.

Clin Cancer Res. 2012 Apr 1;18(7):1827-9. doi: 10.1158/1078-0432.CCR-12-0153. Epub 2012 Mar 26.

PMID:
22451620
[PubMed - indexed for MEDLINE]
Free Article
13.

Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.

Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G, Chung J, Kalmus J, Kappeler C, Schlumberger M.

BMC Cancer. 2011 Aug 11;11:349. doi: 10.1186/1471-2407-11-349.

PMID:
21834960
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Targeted inhibition of CD133+ cells in oral cancer cell lines.

Damek-Poprawa M, Volgina A, Korostoff J, Sollecito TP, Brose MS, O'Malley BW Jr, Akintoye SO, DiRienzo JM.

J Dent Res. 2011 May;90(5):638-45. doi: 10.1177/0022034510393511. Epub 2011 Jan 10.

PMID:
21220361
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIK.

Neely RJ, Brose MS, Gray CM, McCorkell KA, Leibowitz JM, Ma C, Rothstein JL, May MJ.

Oncogene. 2011 Jan 6;30(1):87-96. doi: 10.1038/onc.2010.396. Epub 2010 Sep 6.

PMID:
20818435
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesion.

Tsygankova OM, Ma C, Tang W, Korch C, Feldman MD, Lv Y, Brose MS, Meinkoth JL.

Mol Cell Biol. 2010 Jul;30(13):3262-74. doi: 10.1128/MCB.01345-09. Epub 2010 May 3.

PMID:
20439492
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.

Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, Storm PB, Biegel JA.

Neuro Oncol. 2010 Jul;12(7):621-30. doi: 10.1093/neuonc/noq007. Epub 2010 Feb 14.

PMID:
20156809
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications.

Keefe SM, Cohen MA, Brose MS.

Clin Cancer Res. 2010 Feb 1;16(3):778-83. doi: 10.1158/1078-0432.CCR-08-2743. Epub 2010 Jan 26. Review.

PMID:
20103668
[PubMed - indexed for MEDLINE]
Free Article
19.

Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment.

Flaherty KT, Brose MS.

Clin Cancer Res. 2009 Dec 15;15(24):7749. No abstract available.

PMID:
20008857
[PubMed - as supplied by publisher]
Free Article
20.

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.

Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Beroukhim R, O'Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna JD, Gazdar AF, Zhu CQ, Brose MS, Cecconello I, Jr UR, Marie SK, Dahl O, Shivdasani RA, Tsao MS, Rubin MA, Wong KK, Regev A, Hahn WC, Beer DG, Rustgi AK, Meyerson M.

Nat Genet. 2009 Nov;41(11):1238-42. doi: 10.1038/ng.465. Epub 2009 Oct 4.

PMID:
19801978
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk